Our partners at Lungevity have launched a campaign to promote comprehensive biomarker testing called No One Missed. This follows on our previous post on the importance of identifying genetic variants within each unique patient’s cancer so a precision medicine treatment plan can be provided.
Molecular biologists and pharmaceutical companies have been able to develop drugs that can uniquely target cancer cells which have that particular genetic or molecular abnormality.
Consequently, these subsets of patients that are treated with ‘targeted’ or ‘biomarker matched’ therapies are able to gain a significant survival benefit.
Unfortunately, not all patients are being universally tested for these biomarkers and a precision treatment plan might be their best option.
Please share the importance of getting comprehensive biomarker testing done. No One Missed is an excellent resource for cancer patients to share with their medical team.